Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02367196 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT02367196 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 60 participants.
The verdict
NCT02367196, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
CC-90002-ST -001 is an open-label, Phase 1, dose escalation clinical study in subjects with advanced, refractory solid and hematologic cancers.
Interventions
- DRUG Rituximab
- DRUG CC-90002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2015-03-12 |
| Est. Completion | 2020-12-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02367196
The ClinicalTrials.gov registry entry for NCT02367196 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT02367196 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02367196 about?
NCT02367196 is a clinical study titled "A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers". CC-90002-ST -001 is an open-label, Phase 1, dose escalation clinical study in subjects with advanced, refractory solid and hematologic cancers.
What is the current status of trial NCT02367196?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2015-03-12. Estimated completion is 2020-12-24.
What interventions are being tested in trial NCT02367196?
The interventions under investigation include: Rituximab (DRUG), CC-90002 (DRUG).
Who is sponsoring clinical trial NCT02367196?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.